Menu ×

HEALTHCARE & PHARMACEUTICAL

Duchenne Muscular Dystrophy Treatment Market Segmentation by Therapy (Exon Skipping Approach, Mutation Suppression, and Others); by Treatment (Corticosteroids, Pain Management Drugs, Physical Therapy, and Others); and by Distribution Channel (Hospitals, Specialty Clinics, Surgical Centers, and Others) – Global Demand Analysis & Opportunity Outlook 2030

  • Text Size:

Extensive insights into the Growth of Duchenne Muscular Dystrophy Treatment Market amidst COVID-19

Get the detailed impact analysis of COVID-19 that has disrupted the entire world and affected many industries.

Request Insights


IN THE NEWS

  • June, 2021: Novartis AG, the leading pharmaceutical company for global drug distribution, announced to collaborate with Hewlett Packard Enterprise to expand its portfolio in medical devices production.

  • May, 2018: The Myositis Association (TMA) announced May as Myositis Awareness Month, to spread awareness regarding the autosomal muscular disease. 

Global Duchenne Muscular Dystrophy Treatment Market Highlights over 2022 – 2030

The global Duchenne muscular dystrophy treatment market is estimated to grow at a CAGR of ~11% over the forecast period, i.e., 2022 – 2030. Duchenne muscular dystrophy is an inherited muscular disorder, which results in extreme weakness in muscles. The growth of the market can be attributed to the increasing demand for treatment for Duchenne muscular dystrophy or DMD, along with rising research activities for the development of new treatment methods. Moreover, the growing prevalence of muscular disorders, backed by poor lifestyle and lack of physical activities, are estimated to boost the market growth. According to the data by the World Health Organization (WHO), 1.71 billion people suffer from musculoskeletal disorders. DMD is a type of myositis, which is why, it has no cure. The growing demand for myositis treatment, is anticipated to positively affect the market growth.

Duchenne Muscular Dystrophy Treatment Market

Get more information on this reportDownload Sample PDF

Furthermore, DMD is a rare genetic disorder, mostly prevalent amongst males. According to the National Organization of Rare Disorders (NORD), DMD affects approximately 1 in every 3,500 male births worldwide. The high share of male population, in the total global population is projected to promote the global market growth. In 2020, 50.415% of the global population, i.e., 3.907 billion people were male, as per the statistics by the World Bank.

Population (in %), Segmented by Gender, 2020

In addition to this, the absence of any permanent treatment for this disorder, along with the growing investment in the R&D activities is estimated to boost the market growth.  According to the World Bank data, 2.204% of the global GDP was spent for R&D activities in 2018. 

R&D Expenditure

The market is segmented by treatment into corticosteroids, pain management drugs, physical therapy, and others, out of which, the pain management drugs segment is anticipated to hold the largest revenue share in the market over the forecast period. This can be accredited to the high demand for pain management drugs, as DMD can be extremely painful. Moreover, it is primarily diagnosed in kids of age between 3-6 years, who have a lower threshold for pain. Such factors are estimated to further boost the segment growth. 

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure per Capita

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Duchenne Muscular Dystrophy Treatment Market Regional Synopsis

On the basis of geographical analysis, the global Duchenne muscular dystrophy treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Asia Pacific region is estimated to witness modest growth over the forecast period on the back of high prevalence of musculoskeletal diseases in the region, along with high male population in the region. For instance, according to the World Bank, in India, 51.964% of the total population is male, in 2020. Moreover, the constant development in public healthcare services, backed by rapid economic growth, are anticipated to boost the market growth.

The market in the North America region is anticipated to gain the largest market share throughout the forecast period on account of the high health awareness amongst the population, along with easy access of quality healthcare in the developed nations. Furthermore, rising concerns amongst authorities, regarding rising prevalence of genetic diseases, is also estimated to boost the market growth.

Duchenne Muscular Dystrophy Treatment Market Share

Get more information on this reportDownload Sample PDF

The global Duchenne muscular dystrophy treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the global Duchenne muscular dystrophy treatment market includes the following segments:

By Therapy

  • Exon Skipping Approach
  • Mutation Suppression 
  • Others

By Treatment

  • Corticosteroids
  • Pain Management Drugs
  • Physical Therapy
  • Others

By Distribution Channel

  • Hospitals
  • Specialty Clinics
  • Surgical Centers
  • Others

Growth Drivers

  • Rising Prevalence of Musculoskeletal Disorders
  • High Share of Male Population Globally
  • Increasing R&D Activities in Healthcare Sector

Challenges

  • Difficult Diagnosis of the Disease
  • Lack of Health Awareness amongst People in Undeveloped Regions

Top Featured Companies Dominating the Market

  • Baxter International, Inc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Eli Lilly and Company
  • Novartis AG
  • Sanofi-aventis Groupe
  • Abbott Laboratories
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Siemens Healthcare GmbH
  • Pfizer Inc.
  • Becton, Dickinson and Company

FREQUENTLY ASKED QUESTIONS


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved